ArticleSurgical neurology international2025
Diffuse midline H3K27-altered glioma in an atypical location mimicking a medulloblastoma.
Article in Surgical neurology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diffuse midline glioma (DMG) with H3 histones in lysine 27 (H3K27) mutation is an aggressive central nervous system tumor that primarily affects children. It often presents with nonspecific neurological symptoms and can mimic other posterior fossa tumors, such as medulloblastoma, on imaging. Due to its poor prognosis and rapid progression, early recognition and accurate diagnosis are crucial for patient management. Case Description: We present the case of a 10-year-old girl who developed progressively worsening neurological symptoms, raising suspicion of a posterior fossa tumor. Initial magnetic resonance imaging findings suggested a diagnosis of medulloblastoma. However, after surgical resection, pathological analysis confirmed the presence of a DMG with an H3K27 mutation. Despite the successful resection of a substantial portion of the tumor, the disease progressed rapidly, with tumor dissemination occurring within six months of diagnosis. Conclusion: This case highlights the importance of considering DMG, particularly with H3K27 alterations, as a differential diagnosis in posterior fossa tumors. The presence of these genetic mutations significantly impacts both treatment decisions and prognosis. The variability in clinical presentation and tumor morphology associated with DMG underscores the need for thorough evaluation to optimize treatment strategies and further our understanding of this complex entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.